Prospective evaluation of aflibercept in pigment epithelial detachments secondary to neovascular age related macular degeneration.

Objective: To assess the efficacy of intravitreal aflibercept in treating visual loss and structural changes in patients with pigment epithelial detachments (PED) secondary to neovascular age-related macular degeneration (nAMD).

Methods: Prospective, exploratory, open-label study (ClinicalTrials.gov Identifier: NCT02142296).